Heat Biologics, Inc. to Present at The MicroCap Conference on April 4th in New York City

Heat Biologics, Inc. to Present at The MicroCap Conference on April 4th in New York City

DURHAM, NC / ACCESSWIRE / March 20, 2017 / Heat Biologics, Inc. (NASDAQ: HTBX, "Heat"), a leader in the development of immunotherapies designed to activate a patient's immune system against cancer, announced today that it will be presenting at this year's The MicroCap Conference on April 4th at 11:30 a.m. in New York City at the Essex House.

About Heat Biologics, Inc.

Heat Biologics, Inc. (NASDAQ: HTBX) is an immuno-oncology company developing novel therapies that are designed to activate a patient's immune system against cancer utilizing an engineered form of gp96, a protein that activates the immune system when cells die. Heat’s highly specific T cell-stimulating therapeutic vaccine platform technologies, ImPACT and ComPACT, in combination with other therapies, such as checkpoint inhibitors, are designed to address three distinct but synergistic mechanisms of action: robust activation of CD8+ "killer" T cells (one of the human immune system's most potent weapons against cancer); reversal of tumor-induced immune suppression; and T cell co-stimulation to further enhance patients' immune response. Currently, Heat is conducting a Phase 2 trial with HS-110 (viagenpumatucel-L) in combination with an anti-PD-1 checkpoint inhibitor to treat patients with non-small cell lung cancer (NSCLC) and a Phase 2 trial with HS-410 (vesigenurtacel-L) in patients with non-muscle invasive bladder cancer (NMIBC).

Heat's wholly-owned subsidiary, Zolovax, Inc., is developing therapeutic and preventative vaccines to treat infectious diseases based on Heat's gp96 vaccine technology, with a current focus on the development of a Zika vaccine in conjunction with the University of Miami.

For more information, please visit www.heatbio.com.

Contact:

Jennifer Almond
Investor and Media Relations
919-240-7133
Investorrelations@heatbio.com

SOURCE: Heat Biologics, Inc.